Curis Lifescien. Stock Price Today (NSE: CURIS)

Curis Lifescien.

127.00+0.00 (+0.00%)
Market Closed

Fundamental Score

...

Curis Lifescien. Share Price — Live NSE/BSE Price, Fundamentals & Analysis

Curis Lifescien. share price today is 127.00, up +0.00% on NSE/BSE as of 17 April 2026. Curis Lifescien. (CURIS) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of 102.67 (Cr). The 52-week high for CURIS share price is N/A and the 52-week low is N/A. At a P/E ratio of 16.80x, CURIS is currently trading below its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 55.32% and a debt-to-equity ratio of 0.96.

Curis Lifescien. Share Price Chart — NSE/BSE Historical Performance

No data
High
127.00
Low
127.00
Volume
0
Change
+0.00%

Curis Lifescien. share price chart: 0.00% return over the past month. 52-week high ₹N/A, 52-week low ₹N/A.

AI Research Briefing

Powered by Gemini · 2026-04-17

Micro-cap pharma with stretched valuation and promoter exit; stay away.

Research Confidence
4.0/10Low
MICRO-CAP DARK HORSEbreakdowncheap

WHAT'S HAPPENING NOW (last 2-4 weeks)

No major catalysts found after live search. The last significant news was on April 10, 2026, when Curis Lifesciences informed the exchange about corporate announcements. Before that, on March 31, 2026, there were announcements regarding the resignation of an independent director.

CORE STORY (THE REAL GAME)

Curis Lifesciences is being priced as a high-growth, undervalued pharma micro-cap. The market is focused on its potential to scale manufacturing and distribution of pharmaceutical formulations.

Why Now
  • Undervalued P/E vs Industry
  • High ROE and ROCE
  • Recent corporate announcements
Potential Catalysts
  • New order wins
  • Positive earnings surprises
  • Acquisition by a larger player
Key Risks
  • Micro/SME cap - liquidity risk
  • Promoter stake decreased by 24.65%
  • High Debt/Equity ratio of 0.96
Institutional Activity

Promoter: 68.03% (Δ -24.65%)

Macro Context

General Indian economy is growing, but pharma faces pricing pressure.

Cash Flow Quality

no

3–6 Month Outlook

If Curis can sustain its growth trajectory and improve its balance sheet, it could become an attractive acquisition target. However, execution risk is high.

Primary Thesis Risk

Promoter exit signals potential governance issues and lack of confidence.

For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.

Returns & Performance

Excellent

Return on Equity (ROE)

55.32%

Profit generated per ₹1 of shareholder equity

Excellent

Return on Capital (ROCE)

34.24%

Returns generated on total capital deployed

Oper. Profit Margin (5Y Avg)

N/A

Average operating profit margin over 5 years

Dividend Yield

0.00%

Annual dividend as % of current share price

Curis Lifescien. Valuation Check

Excellent

Price to Earnings (P/E)

16.80x

Share price ÷ earnings per share. Lower = cheaper

Poor

Industry Avg P/E

31.77x

Average P/E of all peers in this sector

Market-cap Classification
Small-cap
Higher growth potential with higher volatility.

Shareholding Pattern

Excellent

Promoter Holding

68.03%

% shares held by company founders/management

Poor

FII Holding

2.93%

% shares held by foreign institutional investors

Good

DII Holding

10.86%

% held by domestic mutual funds, LIC, banks

Excellent

Promoter Pledged %

0.00%

% of promoter shares pledged as collateral — lower is safer

Growth Engine

Profit Growth (Quarterly YoY)

N/A

Net profit growth vs same quarter last year

Revenue Growth (Quarterly YoY)

N/A

Revenue growth vs same quarter last year

Revenue Growth (5-Year CAGR)

N/A

Compounded annual revenue growth over 5 years

EPS Growth (5-Year CAGR)

N/A

Earnings per share growth over 5 years

Net Profit Growth (5-Year CAGR)

N/A

Compounded annual net profit growth over 5 years

Balance Sheet Health

Poor

Debt to Equity Ratio

0.96x

Total debt ÷ equity. Below 0.5 = financially healthy

Excellent

Interest Coverage Ratio

8.45x

EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably

Free Cash Flow (5-Year Total)

N/A

Cash left after capex over 5 years. Positive = self-funded growth

Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice

Curis Lifescien. Fundamental Analysis & Valuation Benchmarking

Educational evaluation of CURIS across key market metrics for learning purposes.

Positive Indicators

6 factors identified

Strong Return on Equity (55.32%)

Observation: Efficient use of shareholders' capital generating superior returns.

Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.

Excellent ROCE Performance (34.24%)

Observation: Superior returns on capital employed across business operations.

Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.

Attractive Valuation (P/E: 16.80 vs Industry: 31.77)

Observation: Trading at discount to industry peers.

Analysis: P/E below industry average may present value opportunity.

Strong Interest Coverage (8.45x)

Observation: Earnings comfortably cover interest obligations.

Analysis: Interest coverage >5x indicates low financial distress risk.

Balanced Promoter Holding (68.03%)

Observation: Optimal balance between promoter control and public float.

Analysis: Promoter holding in 50-75% range provides management alignment.

Zero Share Pledging Risk

Observation: No promoter shares pledged as collateral.

Analysis: Absence of share pledging eliminates potential forced-selling pressure.

Risk Factors

1 factors identified

No Dividend Distribution

Observation: Company does not currently pay dividends to shareholders.

Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.

Curis Lifescien. vs Pharmaceuticals Peers

Peer Comparison -

Compare Curis Lifescien. with 10 other companies in the same sector

11 companies
Company Info
Fundamental
Valuation
Profitability
Financial Health
Growth
Dividend
Company
Company name
Score
Bull Run comprehensive fundamental score based on 20+ metrics
Price
Current trading price of the stock
Market Cap
Total value of all shares in the market
P/E
Price per share divided by earnings per share
ROE
Net income divided by shareholder equity
ROCE
Earnings before interest and tax divided by capital employed
Debt/Eq
Total debt divided by total equity
Profit 5Y
Average annual profit growth over 5 years
Sales 5Y
Average annual sales growth over 5 years
Dividend
Annual dividend per share divided by price per share
7.3/100
127
₹102.67
16.8
Average
55.32%
Excellent
34.24%
Excellent
1.0
Good
0.00%
65.2/100
1844
₹433738.68
37.6
Average
16.86%
Good
20.21%
Excellent
0.1
Excellent
23.78%
Excellent
9.87%
Good
0.89%
67.9/100
6798
₹170445.88
68.6
Average
15.35%
Good
20.44%
Excellent
0.0
Excellent
10.41%
Good
11.65%
Good
0.47%
65.3/100
4538
₹126430.62
58.4
Average
26.52%
Excellent
27.05%
Excellent
0.3
Excellent
13.84%
Good
7.72%
Good
0.86%
Cipla Ltd...
CIPLA500087
59/100
1418
₹123059.76
22.6
Average
17.77%
Good
22.72%
Excellent
0.0
Excellent
28.68%
Excellent
9.97%
Good
0.85%
59.2/100
1319
₹105224.96
18.2
Average
17.96%
Good
22.69%
Excellent
0.2
Excellent
22.28%
Excellent
13.26%
Good
0.63%
Lupin Ltd...
LUPIN500257
66.7/100
2276
₹95148.15
22.0
Average
20.62%
Excellent
21.30%
Excellent
0.3
Excellent
54.88%
Excellent
8.11%
Good
0.58%
68.7/100
957
₹94253.78
18.7
Average
21.21%
Excellent
24.31%
Excellent
0.4
Excellent
25.92%
Excellent
10.27%
Good
1.17%
50.6/100
2420
₹92012.53
52.6
Average
14.68%
Average
15.98%
Good
0.6
Good
11.73%
Good
15.79%
Excellent
0.04%
28.8/100
1436
₹70798.69
20.7
Average
11.08%
Average
14.18%
Average
0.2
Excellent
3.87%
Average
6.55%
Good
0.33%
59.5/100
5452
₹67075.29
28.5
Average
19.39%
Good
20.38%
Excellent
0.2
Excellent
13.93%
Good
9.21%
Good
0.80%

Curis Lifescien. Quarterly Performance

Latest quarterly metrics for CURIS — revenue growth and profit growth vs same quarter last year

Revenue Growth (YoY)

N/A

Latest quarter vs same quarter previous year

Net Profit Growth (YoY)

N/A

Latest quarter net profit vs same quarter previous year

5-Year Revenue CAGR

N/A

Compounded annual revenue growth over 5 years

5-Year Profit CAGR

N/A

Compounded annual net profit growth over 5 years

Curis Lifescien. Financial Statements

Annual income statement, balance sheet and cash flow for Curis Lifescien. (CURIS) — sourced from NSE/BSE filings.

Loading Financial Statements...

Fetching financial data for Curis Lifescien.

About CURIS (Curis Lifescien.)

Curis Lifescien. (CURIS) is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) of India. The company operates in the Pharmaceuticals sector with a current ...market capitalisation of ₹102.67 (Cr). Curis Lifescien. has delivered a Return on Equity (ROE) of 55.32% and a ROCE of 34.24%. The debt-to-equity ratio stands at 0.96, reflecting the company's capital structure. Investors tracking CURIS share price can monitor key metrics including P/E ratio, promoter holding of 68.03%, and quarterly earnings growth.

Company Details

Symbol:CURIS
Industry:Pharmaceuticals
Sector:N/A
Website:N/A

CURIS Share Price: Frequently Asked Questions

What is the current share price of Curis Lifescien.?

Curis Lifescien. (CURIS) trades at ₹127.00 on NSE. Market cap ₹102.67 (Cr). Educational data only.

What is the P/E ratio of Curis Lifescien.?

Curis Lifescien. has a P/E of 16.80x vs industry average 31.77x.

What is the Bull Run score for Curis Lifescien.?

Curis Lifescien. has a Bull Run score of 7.3/100 based on 25+ financial parameters.

Does Curis Lifescien. pay dividends?

Curis Lifescien. has a dividend yield of 0.00%. Past dividends don't guarantee future payments.

What is the ROE of Curis Lifescien.?

Curis Lifescien. has ROE of 55.32%. Higher ROE indicates better use of shareholder equity.

What is the debt-to-equity ratio of Curis Lifescien.?

Curis Lifescien. has debt-to-equity of 0.96.

Is Curis Lifescien. a good investment?

Bull Run gives Curis Lifescien. a score of 7.3/100. This is not investment advice — consult a SEBI-registered advisor.